4/A: AbbVie Executive Roopal Thakkar Corrects Stock Ownership and Option Details in Amended SEC Filing
SEC Filing (Form 4/A)
Roopal Thakkar, EVP, R&D and CSO of AbbVie, files an amendment to a previous SEC Form 4 to correct errors in reported stock awards and option exercise price.
Summary
- Roopal Thakkar, an executive at AbbVie, filed an amended Form 4 with the SEC to correct previously reported information.
- The amendment addresses errors in the award amounts of common stock and the exercise price of options granted on February 15, 2024.
- The corrected filing shows Thakkar's beneficial ownership of AbbVie common stock, including shares acquired through performance share awards and restricted stock units.
- The corrected exercise price for the options awarded on February 15, 2024, is $175.28.
- Thakkar directly owns 41,313 shares of AbbVie common stock following the reported transactions.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing. The correction of errors is a neutral event, but transparency is generally viewed positively.
Negatives
- The need for an amendment indicates an initial administrative error in reporting stock awards and option details.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting and exercisability schedules of the stock options and awards.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like AbbVie. It provides transparency to investors regarding the alignment of management's interests with those of shareholders.
Comparison to Industry Standards
- Executive compensation packages, including stock options and awards, are standard practice among large pharmaceutical companies like AbbVie, Johnson & Johnson, Pfizer, and Merck.
- The vesting schedules and performance-based conditions attached to these awards are also typical, designed to incentivize long-term value creation.
- The specific terms of Thakkar's awards (e.g., performance metrics, vesting periods) would need to be compared against peer companies to assess their relative competitiveness and alignment with industry norms.
Stakeholder Impact
- The correction of information ensures accurate reporting to shareholders and the public.
- The vesting of performance-based awards aligns executive compensation with company performance, potentially benefiting shareholders.
Key Dates
| Date | Description |
|---|---|
| 02/15/2024 | Date of earliest transaction and grant date for stock options. |
| 02/20/2024 | Date of original Form 4 filing that contained errors. |
| 02/28/2024 | Date shares will be issued to the reporting person. |
| 02/15/2025 | First date options become exercisable (7,775 options). |
| 02/15/2026 | Second date options become exercisable (7,775 options). |
| 02/15/2027 | Third date options become exercisable (7,774 options). |
| 02/14/2034 | Expiration date of the options. |
| 02/07/2025 | Date of signature on the amended form. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.